Chinook Therapeutics has received a consensus rating of Buy.
Is pliant Therapeutics a buy?
Pliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Should I invest in Karuna Therapeutics?
There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Karuna Therapeutics stock.
How many employees does Karuna therapeutics have?
Karuna Therapeutics Annual Number of Employees
----------------------------------------------
2018
How many employees at Karuna?
Karuna Therapeutics Annual Number of Employees
----------------------------------------------
2019
2018